Atropine Sulfate Injection
Product Images NDC 51662-1619

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Atropine Sulfate (NDC 51662-1619). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pouch (51662 1619 2 Pouch Label)

Label for Atropine Sulfate Injection, USP 8 mg per 20 mL vial (0.4 mg/mL). The vial is labeled for multiple routes of administration including intravenous, intramuscular, subcutaneous, intraosseous, endotracheal, and intramedullary. The label also includes NDC 51662-1619-2, storage instructions, and manufacturer information identifying HF Acquisition Co LLC, DBA HealthFirst in Mukilteo, WA.*

FDA Label Image

Case (51662 1619 3 Case Label)

Label for ATROPINE SULFATE injection, USP 8 mg/20 mL (0.4 mg/mL) in a 20 mL vial, sold as a case of 10. The label includes NDC 51662-1619-3 and manufacturer information for HF Acquisition Co LLC, DBA HealthFirst. It indicates multiple routes of administration including endotracheal, intramedullary, intramuscular, intravenous, and subcutaneous.*

FDA Label Image

Rfid (51662 1619 3 Serialized Rfid Label)

ATROPINE SULFATE injection label showing 0.4 mg/mL strength. The label includes a 2D barcode and identification numbers. It notes distribution by HF Acquisition Co LLC, DBA HealthFirst, located in Mukilteo, WA 98275. The label also indicates 'RX ONLY.'*

FDA Label Image

D1 (D 1)

A dosing instruction table for Atropine Sulfate Injection 0.4 mg/mL. It includes initial dose, continued treatment, maximum total dose, and maintenance dose information for various uses including anticholinergic, anti-viral, preanesthesia and during surgery, organophosphate poisoning, symptomatic bradycardia, and other conditions. The table specifies dosage amounts, frequency, and administration routes.*

FDA Label Image

D Inter (Drug Inter)

A text excerpt discussing Atropine Sulfate Injection and its effect on the rate of mexiletine absorption, noting that atropine decreases absorption rate without changing relative oral bioavailability and that this delay can be reversed by combining atropine with intravenous metoclopramide during anesthesia pretreatment.*

FDA Label Image

Structure (Structure)

Chemical structure of atropine sulfate, showing two atropine molecules with sulfate and water molecules as part of the compound.*

FDA Label Image

Specific Pop (Use In Specific)

Text from Atropine Sulfate Injection labeling discussing limited data on use in pregnant women, risks to mother and fetus from untreated muscarinic events, and that animal reproduction studies have not been conducted with this drug.*

FDA Label Image

Vial (Vial Label)

Label for Atropine Sulfate Injection, USP, 0.4 mg/mL (8 mg per 20 mL) in a 20 mL multiple-dose vial. Intended for intravenous, intramuscular, subcutaneous, intraosseous, or endotracheal use. The label includes active ingredient concentration, storage instructions requiring temperature between 20° to 25°C and discard within 24 hours after initial use, and manufacturer HF Acquisition Co LLC, DBA HealthFirst, Berkeley Heights, NJ.*

FDA Label Image

D2 (D 2)

A data table presenting initial doses, continued treatment, and maximum doses for various clinical uses of atropine sulfate injection, including antisialagogue, organophosphate poisoning, and other conditions such as symptomatic bradycardia and increased vagal tone. Dosage details are given for different age groups and administration routes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.